Literature DB >> 17403688

Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.

Giorgio Pochetti1, Cristina Godio, Nico Mitro, Donatella Caruso, Andrea Galmozzi, Samuele Scurati, Fulvio Loiodice, Giuseppe Fracchiolla, Paolo Tortorella, Antonio Laghezza, Antonio Lavecchia, Ettore Novellino, Fernando Mazza, Maurizio Crestani.   

Abstract

The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of glucose and lipid metabolism. They are activated by natural ligands, such as fatty acids, and are also targets of synthetic antidiabetic and hypolipidemic drugs. By using cell-based reporter assays, we studied the transactivation activity of two enantiomeric ureidofibrate-like derivatives. In particular, we show that the R-enantiomer, (R)-1, is a full agonist of PPARgamma, whereas the S-enantiomer, (S)-1, is a less potent partial agonist. Most importantly, we report the x-ray crystal structures of the PPARgamma ligand binding domain complexed with the R- and the S-enantiomer, respectively. The analysis of the two crystal structures shows that the different degree of stabilization of the helix 12 induced by the ligand determines its behavior as full or partial agonist. Another crystal structure of the PPARgamma.(S)-1 complex, only differing in the soaking time of the ligand, is also presented. The comparison of the two structures of the complexes with the partial agonist reveals significant differences and is suggestive of the possible coexistence in solution of transcriptionally active and inactive forms of helix 12 in the presence of a partial agonist. Mutation analysis confirms the importance of Leu(465), Leu(469), and Ile(472) in the activation by (R)-1 and underscores the key role of Gln(286) in the PPARgamma activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403688     DOI: 10.1074/jbc.M702316200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Resveratrol and its metabolites bind to PPARs.

Authors:  E Calleri; G Pochetti; K S S Dossou; A Laghezza; R Montanari; D Capelli; E Prada; F Loiodice; G Massolini; M Bernier; R Moaddel
Journal:  Chembiochem       Date:  2014-05-05       Impact factor: 3.164

2.  Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor.

Authors:  Andreas Bock; Marcel Bermudez; Fabian Krebs; Carlo Matera; Brian Chirinda; Dominique Sydow; Clelia Dallanoce; Ulrike Holzgrabe; Marco De Amici; Martin J Lohse; Gerhard Wolber; Klaus Mohr
Journal:  J Biol Chem       Date:  2016-06-13       Impact factor: 5.157

3.  Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models.

Authors:  Stephanie Kim; Amy Li; Stefano Monti; Jennifer J Schlezinger
Journal:  Arch Toxicol       Date:  2018-07-19       Impact factor: 5.153

4.  Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.

Authors:  Laura Guasch; Esther Sala; Cristina Valls; Mayte Blay; Miquel Mulero; Lluís Arola; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  J Comput Aided Mol Des       Date:  2011-06-21       Impact factor: 3.686

5.  N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.

Authors:  Kavita Bhalla; Bor Jang Hwang; Jang Hyun Choi; Ruby Dewi; Lihui Ou; John Mclenithan; William Twaddel; Edwin Pozharski; Jeffry Stock; Geoffrey D Girnun
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

6.  Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.

Authors:  Letizia Giampietro; Antonio Laghezza; Carmen Cerchia; Rosalba Florio; Lucia Recinella; Fabio Capone; Alessandra Ammazzalorso; Isabella Bruno; Barbara De Filippis; Marialuigia Fantacuzzi; Claudio Ferrante; Cristina Maccallini; Paolo Tortorella; Fabio Verginelli; Luigi Brunetti; Alessandro Cama; Rosa Amoroso; Fulvio Loiodice; Antonio Lavecchia
Journal:  ACS Med Chem Lett       Date:  2019-02-25       Impact factor: 4.345

7.  Pharmacophore-driven identification of PPARγ agonists from natural sources.

Authors:  Rasmus K Petersen; Kathrine B Christensen; Andreana N Assimopoulou; Xavier Fretté; Vassilios P Papageorgiou; Karsten Kristiansen; Irene Kouskoumvekaki
Journal:  J Comput Aided Mol Des       Date:  2010-11-11       Impact factor: 3.686

8.  Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment.

Authors:  Vinicius G Maltarollo; Paula Homem-de-Mello; Kathia M Honório
Journal:  J Mol Model       Date:  2009-12-12       Impact factor: 1.810

Review 9.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

10.  Virtual Screening as a Technique for PPAR Modulator Discovery.

Authors:  Stephanie N Lewis; Josep Bassaganya-Riera; David R Bevan
Journal:  PPAR Res       Date:  2009-09-02       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.